Industry News

TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma

12/08/2020

Excerpt from the Press Release: BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) — TearClear, an emerging ophthalmic pharmaceutical company, today announced successful completion of pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development plan for the preservative free multi-dose delivery of a proprietary Latanoprost formulation, including the clinical study…

Read More

MapLight Therapeutics Announces Completion of Dosing in Phase 1 Study of Therapy for Social Deficit in Autism Spectrum Disorder

12/07/2020

Excerpt from the Press Release: SAN FRANCISCO, Nov. 23, 2020 /PRNewswire/ — MapLight Therapeutics today announced it has completed dosing of healthy volunteers across five cohorts in a Phase 1 clinical trial evaluating the safety of ML-004, a selective serotonin receptor agonist. Based on results from the study to date, ML-004, which MapLight intends to evaluate…

Read More

Persephone Biosciences Initiates the ARGONAUT Study of Gut Microbiome-Linked Immune Modulation in Cancer Treatment Response

12/06/2020

Excerpt from the Press Release: SAN DIEGO, Nov. 23, 2020 /PRNewswire/ — Persephone Biosciences Inc., a biotechnology company that leverages real world data and artificial intelligence to design microbiome therapeutics and diagnostics to promote normal immune function and fight disease, today announced the initiation of the ARGONAUT clinical study to determine the impact of gut microbiome…

Read More

BigBio Communications Launches The BioCalendar, The Premier Industry Calendar for Life Science Conferences and Events

12/05/2020

Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–BigBio Communications, developer of the life science industry news aggregator Big4Bio, proudly announces the launch of The BioCalendar (TheBioCalendar.com), an exclusive event listing platform for the global healthcare and biopharmaceutical industry. The BioCalendar was created to be the comprehensive calendar and guide for healthcare and life science industry…

Read More

CASTL supports life sciences students and industry growth with Financial Award program

12/04/2020

Excerpt from the Article: Charlottetown, PE – The Canadian Alliance for Skills and Training in Life Sciences (CASTL) announced today Financial Awards of $5,000 for 32 post-secondary students across Atlantic Canada to support their academic studies in life sciences. This Financial Award program will support life sciences students enrolled in co-operative education from Acadia University, Université…

Read More

Common Anti-Inflammatory Drug Added to COVID-19 Treatment Study

12/04/2020

Excerpt from the Press Release: United Kingdom (Precision Vaccinations) A commonly used anti-inflammatory treatment has been added to the Randomised Evaluation of COVid-19 thERapY (RECOVERY) study, the world’s largest clinical trial of treatments for patients hospitalized with COVID-19. Professor Peter Horby at the University of Oxford and co-Chief Investigator of the RECOVERY trial, said in…

Read More

Pfizer Covid Vaccine Faces Hurdles After FDA Filing Friday

12/03/2020

Excerpt from the Article: Pfizer Inc. and BioNTech SE requested emergency authorization of their Covid vaccine on Friday, and it could take at least three weeks for a U.S. Food and Drug Administration decision as trial data is probed by agency staff and outside advisers. Shown to be 95 percent effective and without any major…

Read More

The important role of CROs in shaping the future of clinical research across Europe

12/02/2020

Excerpt from the Article: It goes without saying that COVID-19 has had a tremendous impact on our global society and economy. In fact, as lockdown was initiated across Europe at the start of March, we quickly saw the impact of this pandemic on clinical research activities across the various regions. Within the life sciences industry,…

Read More

Fluvoxamine May Prevent Clinical Deterioration in Mild COVID-19

12/02/2020

Excerpt from the article: Fluvoxamine, an antidepressant used to treat obsessive-compulsive disorder, may help prevent clinical deterioration of patients with mild coronavirus disease 2019 (COVID-19), results of an early clinical trial suggest. The double-blind, placebo-controlled, randomized study, published in JAMA, included 152 outpatients with COVID-19 in the St. Louis area between April 10 and August…

Read More

Profound Medical Receives FDA HDE Approval for Sonalleve®

12/01/2020

Excerpt from the Press Release: TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX: PRN) (“Profound” or the “Company”) announced today that Sonalleve® has received U.S. Food and Drug Administration (“FDA”) approval under a Humanitarian Device Exemption (“HDE”) for the treatment of osteoid osteoma. Osteoid osteoma is a non-cancerous bone tumor that…

Read More